476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS
No abstract is available for this record.
Bibliographic context
- Journal
- Unknown
- Date
- 2025-07-31
- Source
- Europe PMC
- DOI
- Unavailable
- PubMed
- Unavailable
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-02Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticityTranslational Psychiatry · 2026-06-04Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapyNatural Product Research · 2026-06-01Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case reportFrontiers in Neuroscience · 2026-05-27Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybinJournal of Pre-Clinical and Clinical Research · 2026-05-11